Authors

• Thomas A Prohaska (ORCID: https://orcid.org/0000-0002-1406-692X)
• Marc S. Sabatine (ORCID: https://orcid.org/0000-0002-0691-3359)
• Robert P. Giugliano (ORCID: https://orcid.org/0000-0003-4110-7675)
• Brian A. Bergmark (ORCID: https://orcid.org/0000-0003-4360-7606)
• Michael T. Lu (ORCID: https://orcid.org/0000-0003-4696-9610)
• Filipe A. Moura (ORCID: https://orcid.org/0000-0001-8017-1675)
• S. M. Zhang
• Veronica J. Alexander (ORCID: https://orcid.org/0000-0003-3729-5749)
• Ewa Karwatowska‐Prokopczuk (ORCID: https://orcid.org/0000-0002-6371-5834)
• André Zimerman (ORCID: https://orcid.org/0000-0001-8977-6929)
• Sabina A. Murphy (ORCID: https://orcid.org/0000-0002-8231-3611)
• Sotirios Tsimikas (ORCID: https://orcid.org/0000-0001-9834-9494)
• Nicholas Marston (ORCID: https://orcid.org/0000-0001-6164-4617)
• Yu Mi Kang (ORCID: https://orcid.org/0000-0002-6272-0666)

Institutions

• Brigham and Women's Hospital (US)
• Ionis Pharmaceuticals (United States) (US)
• Hospital Moinhos de Vento (BR)
• VA Connecticut Healthcare System (US)
• Massachusetts General Hospital (US)
• Thrombolysis in Myocardial Infarction Study Group (US)

Publication Details

Journal

American Heart Journal

Published

2025-03-11

DOI

https://doi.org/10.1016/j.ahj.2025.02.022

Citations

8

Primary Topic

Lipid metabolism and disorders

Type

article

Field-Weighted Citation Impact

11.11

Funders

• Amgen
• Beckman Coulter Foundation
• AstraZeneca
• Ionis Pharmaceuticals
• MedImmune
• Fundação Lemann
• National Institutes of Health
• National Heart, Lung, and Blood Institute
• Janssen Pharmaceuticals